Scholars Central

Conference abstractPublished 21 Oct 2013

Adherence to IEC62366 may not ensure a successful FDA review: A case study

Authors: Dean Hooper

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Compliance to ISO/IEC 62366 ensures the medical device manufacturer has performed due diligence in the design and development of the product so as to minimize the risk of harmful use error. This standard also lays out a user centered design process that should enhance the product?s general usability once market released. It has expanded the scope of its preceding standard, which was solely for electrical medical devices (ISO/IEC 60601-1-6: Medical electrical equipment - part 1-6: General requirements for safety - Collateral standard: Usability), to include all medical devices. The 62366 standard is often used when applying for a product?s CE Mark. In essence, the device manufacturer may choose to show that activities have been performed for the specific product of interest or demonstrate that their overall product development process adheres to 62366. And it has become common for manufacturers to submit such compliance to the FDA for US release; especially for those attempting to enter the US market after CE mark. However, for a successful market release in the US, adherence to IEC62366 may be necessary but definitely not sufficient for a successful FDA review. In fact, the FDA has pointedly responded to the industry due to new product and 510 k submissions that tout such compliance as evidence use error has been investigated. They explicitly state they will not accept compliance alone as evidence that the design of the product would minimize the occurrence of use error. Through a case study, this presentation will detail the common FDA review comments concerning IEC62366 compliance. Details will be presented on how these discrepancies were successfully addressed and, ultimately, how to avoid initial obstacles all together by outlining the FDA human factors review guidelines currently in effect.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dean Hooper”